ALEPH-FARMS
16.3.2022 13:03:30 CET | Business Wire | Press release
Aleph Farms , the first company to grow cultivated beef steaks, today announced it is expanding its product line to include a unique platform for cell-cultured collagen production. The company’s highly differentiated, integrated strategy to develop a complete alternative to animals in intensive animal farming is a testament to its inclusive vision to supplement sustainable, but less productive, livestock agriculture practices.
“The cellular agriculture industry has made greater promises to replace a large part of intensive animal farming practices, which make up to 70% of the global meat production. Cultivated meat, however, is only part of that solution as meat represents just 30-35% of the cow that is slaughtered. The rest include many other valuable by-products. To achieve our vision, we need to provide alternatives to the other animal parts as well, including collagen-based products,” said Didier Toubia, co-founder and CEO of Aleph Farms. “Focusing on single categories of animal products does not account for the complexity of the animal agriculture ecosystem. The protein transition should rely on a systems-based approach to successfully contribute to a comprehensive, just and inclusive transition for animal agriculture.”
Conventional collagen is produced by boiling and processing cow’s hides and bones, and is widely used in a range of industries. Aleph Farms' cultivated collagen offers attributes of natural animal-based collagen that are unmatched by plant or fermented recombinant-based alternatives.
Aleph Frontiers is a division of Aleph Farms’ research center focused on the development of new technologies and products for eventual commercialization. As the first product to emerge from the company’s newly revealed incubator, and following 18 months of research by an expert team in stealth mode, Aleph’s collagen is now moving to full product development stage and should launch in 2024.
“We are leveraging key components from our production method for steaks—including our bovine cell sources and animal component-free growth medium—to produce several nature-identical collagen types directly from cow cells, as well as the entire extracellular matrix (ECM) which comprises a variety of fiber-forming proteins and represents the complete matrix of skin, bones and joints,” said Dr. Neta Lavon, CTO and VP of R&D at Aleph Farms. “Collagen is the most abundant protein in the ECM and is well recognized for its benefits.”
This announcement follows the company’s expansion to its new cultured-beef steaks pilot production plant. Both platforms largely share similar inputs and equipment and present operational and cost-reduction synergies.
About Aleph Farms
Aleph Farms grows cultivated beef steaks, from non-genetically engineered cells, that are not immortalized, isolated from a living cow, without slaughtering the animal and with a significantly reduced impact to the environment. The company was co-founded in 2017 by Didier Toubia, The Kitchen Hub of the Strauss Group, and Professor Shulamit Levenberg from the Biomedical Engineering Faculty at the Technion - Israel Institute of Technology. The company’s vision is to provide unconditional nutrition for anyone, anytime, anywhere. For more information, follow Aleph Farms on Instagram , Twitter , Facebook or LinkedIn or visit www.aleph-farms.com . Access the Aleph Farms press kit here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005177/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
